In vivo glutamine synthetase activities measured at several levels of hyperammonemia showed that this enzyme becomes saturated at blood ammonia concentration >0.9 mmol/g, and causes the elevation of brain ammonia. Implications of the results for the cause of hyperammonemic encephalopathy are discussed. Leucine provides >25% of glutamate nitrogen. An intriguing possibility that supplementing leucine may restore cognitive function after brain injury is discussed. Finally, some characteristics of 15 N MRS that may facilitate the future application of this technique to the study of the human brain at 4 or 7 T are described.
Introduction
In vivo 15 N magnetic resonance spectroscopy (MRS) is a useful technique that has made a unique contribution to our understanding of metabolic flux. The in vivo studies were first performed in microorganisms (reviewed by Ref. [1] ) and since the 1990's in the mammalian brain (reviewed by Refs. [2, 3] ). Brain metabolites of neuropathological importance include glutamate (GLU), which mediates most of the excitatory neurotransmission, and glutamine (GLN) which is closely linked to glutamate in the glutamine/glutamate "cycle". Fig. 1 shows schematically the major metabolic and transport pathways of GLU and GLN in the neuron, the glia, and the extracellular compartment of the brain. The neurotransmitter GLU (GLU NT ) is released from presynaptic vesicles in axon terminals to the extracellular fluid (ECF) and binds to the receptor of the postsynaptic neuron for neurotransmission. It is then mainly taken up into the glia by the excitatory amino acid transporter subtype 2 (EAAT2) and metabolized to GLN by glia-specific glutamine synthetase (GS). The rapid clearance of the glutamate in the extracellular fluid (GLU ECF ) from the synaptic space prevents the excessive stimulation of the GLU receptor (GLU excitotoxicity) which is implicated in a wide range of neurological disorders [4e6] . GLN is then transported from glia to the extracellular fluid by the sodium-coupled neutral amino acid transporter subtype 3 (SNAT3) [7, 8] and possibly by the subtype 5 (SNAT5) (Section 3.1.1). Glutamine in the extracellular fluid (GLN ECF ) is taken up into neurons by the sodium-coupled neutral amino acid transporter subtypes 1 and 2 (SNAT1 and 2) [9, 10] . (Corresponding earlier nomenclatures for the transporters are given in Fig. 1 caption) . Neuronal GLN is then hydrolyzed, by phosphate-activated glutaminase (GLNase), to GLU. According to the concept of the glutamine/glutamate cycle [11, 12] , this completes the recycling of GLU from GLN. An aminotransferase, viz. branched-chain aminotransferase (BCAT), also contributes to GLU synthesis from leucine [13e15]. These major pathways control the flux of the metabolic and neurotransmitter pools of GLU and involve the formation or transfer of amide and amine groups. Hence, non-invasive 15 N MRS makes a unique contribution to the kinetic studies of these individual pathways in vivo. The classical study by Berl et al. [16] which examined 15 N labeling of brain glutamate and glutamine in 15 NH 4 þ -infused cat led to the important concept of compartmentation of glutamate metabolism in the brain: there is a small pool that rapidly turns over that is kinetically distinct from a larger pool that slowly turns over. Using 13 N, the positron-emitting isotope with a half-life of 10 min that can be easily quantified, Cooper et al. measured the brain uptake index of ammonia [17] and its incorporation into glutamine. While the 13 N studies clearly demonstrated the importance of glutamine synthetase in the metabolism of brain ammonia, these short-term (10e25 min) experiments did not provide a numerical estimate of the rate of glutamine synthesis in the brain (reviewed by Ref. [18] ). Measurement of the in vivo glutamine synthetase activity in the rat brain using 15 N MRS was initiated in our laboratory at 4.7 T in the 1990s and then in other laboratories at higher field strengths (7 and 9.4 T) (Section 3.1).
Methodology of 15 N MRS

Characteristics of in vivo 15 N MRS
The most abundant isotope of nitrogen, 14 N (natural abundance 99.6%), has seldom been used for in vivo MRS because it has a nuclear spin quantum number I ¼ 1 and hence a quadrupole moment, leading to rapid relaxation and broad signals in most molecules of biomedical importance. We will focus on 15 N which has a nuclear spin I ¼ ½ and provides a MRS signal with a narrow linewidth. First, the characteristics of 15 N MRS (by direct 15 N detection) that are important for in vivo studies are described.
Direct 15 N detection
15
N has a high spectral resolution because of its broad chemical shift range (500e900 ppm) [19] . Its low natural-abundance (0.365%) is an advantage for in vivo MRS because only those metabolites that have been 15 N enriched by the intravenous infusion of a labelled precursor are normally observed, without interference from naturally occurring 15 N. This permits the measurement of the fluxes of 15 N-metabolites upon a clean background. The sensitivity of 15 N is 1/1000 th of that of 1 H and 1/15th of that of 13 C for equal numbers of nuclei at a constant field. However, proton-decoupling not only removes 15 N-1 H splitting, but can also lead to the enhancement of the 15 N signal by the nuclear Overhauser effect (NOE) for 15 N nuclei that relax via dipolar interaction with proton(s). Due to the negative gyromagnetic ratio of 15 N, the nuclear Overhauser enhancement factor (NOEF) is negative, with a theoretical maximum value of À4.93. This NOEF, when added to the original signal intensity (þ1.0), results in an inverted and enhanced signal with a maximum NOE enhancement of À3.93 [19] . Nearmaximum NOE is observed in many molecules of biomedical importance, such as GLU and GLN. The spin-lattice relaxation times, T 1 , of these nitrogens are relatively short, < 5 s, permitting fairly rapid signal acquisition. Consequently, 15 N enriched brain metabolites in the 1e10 mM range can be observed with a time resolution of 5e30 min by proton-decoupled NOE-enhanced 15 [20] . The time resolution permits the measurement of the reaction rates on the order of 0.1e10 mmol/g/h, which comprise the in vivo rates of many key reactions that control the flux of GLU. N heteronuclear multiple-quantum coherence (HMQC) transfer MRS [23] and heteronuclear single-quantum correlation (HSQC) MRS [24] . These methods permit the selective detection of 1 H spin-coupled to 15 N if the proton is non-labile at physiological pH and temperature. 15 N are suppressed by phase-cycling. As an interesting aside, the observation of the line-broadening of H Z , due to base-catalyzed exchange with water proton, has provided a unique assay of the glial pH (~7.5) in severe hyperammonemia [27] , whereas whole brain pH was unchanged in moderate hyperammonemia [28] compared to that in the normal rat, which is reported to be pH 7.1 (reviewed by Chesler [29] Fig. 4 and described below, followed by a description of the third approach developed in other laboratories. 
Indirect
Localization
For the localized observation of brain 15 N-metabolites, we used image-selected in vivo spectroscopy (ISIS) developed by Ordidge et al. [32] . In Fig. 2 , the bottom spectrum shows an 15 N spectrum of [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] N]GLN in the rat brain, acquired with three-dimensional ISIS in 28 min in a volume probe with a homogeneous B 1 field. An alternative localization method is surface-coil localization, which has been used successfully in an 15 N NMR study of the rat brain at 7 T [21] . More recently, Cudalbu et al. [22] used a single-shot inversion recovery based non-echo (SIRENE) sequence to obtain localized 15 N spectra from the rat brain at 9.4 T. This sequence was originally developed for 13 C MRS [33] . The effects of the field strength and localization methods on the signal-to-noise ratio of the brain [5- 15 N]GLN are discussed in Section 3.1.2.
Applications
3.1. In vivo glutamine synthetase activity 3.1.1. In vivo GS activity as a function of blood [NH 3 ] e implications for the etiology of hyperammonemic encephalopathy Glutamine synthetase (GS) plays an important role in protecting the brain from several diseases. One is hepatic encephalopathy (HE) which is a metabolic disorder of the brain caused by liver dysfunction and by inborn errors of single genes resulting in defects in the hepatic urea cycle (ornithine transcarbamylase deficiency), reviewed, for example, by Braissant et al. [34] . The mechanisms responsible for the pathogenesis of HE are unresolved (reviewed by Desjardins et al. [35] ). Decreased ammonia removal in the liver causes hyperammonemia and diffusion of excess ammonia into the brain. Ammonia is metabolized to GLN by glutamine synthetase in glia ( Fig. 1 ), but ammonia can accumulate if the rate of its influx exceeds the rate of its removal by GS. Whether the neurotoxicity of ammonia itself causes encephalopathy or whether the concomitant accumulation of GLN, which is known to cause brain edema, contributes to pathogenesis by "osmotic gliopathy" [36] has been the subject of considerable debate [35, 37] .
Most early investigations of a possible correlation between the degree of encephalopathy and brain ammonia and GLN concentrations in experimental animals used portacaval-shunted rats with hepatic artery ligation [38e40]. (For a recent review on other animal models of acute and chronic liver failure, see Braissant et al. [34] ). While portacaval-shunted rats with hepatic artery ligation are good models of acute HE, the complete loss of liver function results in coma and death in 6e10 h, and the effects of hyperammonemia are often difficult to separate from the other effects of irreversible liver failure. Hyperammonemia induced by the administration of ammonia in rats with normal liver functions avoids this problem and has the additional advantage that the reversal of encephalopathy can be studied. In our study, hyperammonemia was induced by the intravenous infusion of NH 4 Ac to attain steady-state blood [NH 3 ]. This permitted the examination of the possible correlation between the severity of encephalopathy, as assessed by neurobehavioral impairments in awake rats, and brain ammonia and GLN concentrations. A unique feature of our study was the measurement of the rates of glutamine synthesis in vivo at several levels of hyperammonemia, to examine how the activity of this enzyme controls the concentrations of brain ammonia and GLN in vivo [41] . As described in Section 2.4, the rate of glutamine synthesis was determined from the observed time-course of [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] N]GLN and the 15 N enrichment of blood ammonia (0.077 ± 0.017), as well as that of brain glutamine (0.24 ± 0.02), to be 4.8 ± 0.1 mmol/h/g (n ¼ 5) at a steady-state blood NH 3 concentration of 0.64 mmol/g [20] . Enrichment is expressed as fractional enrichment (Section 2.5).
For the kinetic study at a near-physiological blood ammonia concentration, we used the more sensitive indirect detection of 15 the linear increase of 1/y with 1/s permitted the estimation of the in vivo GS activity at the physiological blood ammonia concentration (0.17 ± 0.018 mmol/g) to be 1.3 ± 0.8 mmol/g/h [30, 41] . The plateau reached by in vivo GS activity (Fig. 7 ) strongly suggested that GS becomes saturated in situ when blood [NH 3 ] exceeds 0.9 mmol/g. Interestingly, this in vivo result is in accord with the reported K m for ammonia of ovine brain GS, 0.18 mM [42] and the K m for ammonia of rat liver GS, 0.3 mM [43] which can be regarded as that of rat brain GS because of the virtually identical amino acid sequences of the two enzymes (discussed in Kanamori et al. [20] ).
The effects of the saturation of GS on brain ammonia concentration and on the grade of encephalopathy observed in corresponding awake rats are shown in Fig. 8 . The grades of encephalopathy, which parallel muscular incoordination progressing to stupor and coma in human HE patients [44] , were assigned according to established criteria [40] . In moderate hyperammonemia (left figure), ammonia diffusing into the brain was incorporated into GLN by GS and the brain ammonia concentration remained at approximately 2 mmol/g during 3e8 h of infusion. The corresponding awake rats showed only Grade III encephalopathy. By contrast, in severe hyperammonemia (right figure), brain ammonia was elevated to 3.5 mmol/g and the rats progressed from grade III to grade IV encephalopathy (For a brief description of Grades III and IV see Fig. 8 caption) . When ammonia infusion was stopped at t ¼ 6 h (bottom x-axis), brain ammonia decreased and the rat recovered to grade III. This result strongly suggests that at this level of hyperammonemia, when the in vivo GS activity became saturated (Fig. 7) , the rate of ammonia influx into the brain exceeded the rate of ammonia incorporation into GLN and the resulting elevation of brain ammonia induced the onset of grade IV encephalopathy.
Because GLN accumulation and the resulting brain edema have also been implicated as a possible cause of encephalopathy [36] , we examined the brain GLN concentration as well (Fig. 9 ). The concentration was very similar in moderate and severe hyperammonemia and showed little correlation with the grade of encephalopathy. Significantly, when glutamine synthesis was inhibited by pre-injection of L-methionine-DL-sulfoximine (MSO), an irreversible inhibitor of GS, given intraperitoneally 4 h before the start of NH 4 Ac infusion at a dose of 55 ± 5 mg/kg, the brain GLN was only 5.5 mmol/g (open circle in the right panel of Fig. 9 ), but the rat showed grade IV encephalopathy. This dose was confirmed to be non-convulsive [41] . Note that these MSO-treated rats with grade IV encephalopathy had a brain [NH 3 ] of 3 mmol/g (open square in Fig. 8) . These results strongly suggested that the elevation of brain [NH 3 ] , not the accumulation of brain GLN, is the cause of encephalopathy in severe hyperammonemia.
In conclusion, this study [41] resolved a controversial issue, viz whether the neurotoxicity of ammonia itself, or the concomitant accumulation of glutamine is the major factor in the pathogenesis of hyperammonemic encephalopathy. This study also provided, for the first time, quantitative evidence for the level of hyperammonemia at which GS becomes saturated, resulting in the accumulation of neurotoxic levels of brain ammonia.
It has recently been proposed [35] that brain edema observed in animal models of acute liver failure is caused by the trapping of newly synthesized glutamine within astrocytes as a consequence of the down-regulation of a glutamine transporter SNAT5 which has been localized to astrocytes [45] . This proposal is based on evidence that HE and brain edema result in a selective loss of the expression of the gene coding for SNAT 5 in the brain [35] . Another laboratory [46] reported a marked reduction in SNAT3 (SN1) and SNAT5 (SN2) expression at the mRNA level and SNAT3 at the protein level, in the cerebral cortex of rats with thioacetamide-induced HE. The reduction coincided with marked cerebral cortex swelling in the same model. Interestingly, SNAT3 and SNAT5 expression remained unaltered in rats with simple hyperammonemia in the ammonium acetate model, where the cerebral cortex volume did not change. Taken together, the results suggest an intriguing possibility that the restricted efflux of newly synthesized glutamine due to regulation of GLN transporters contributes to brain edema in acute liver failure. However, whether SNAT5 is as widely distributed and is as important a mediator of GLN efflux in the brain as SNAT3 [7] , remain questions for future investigation [46] .
In vivo GS activities in hyperammonemia as determined by metabolic modeling at higher magnetic field strengths
Shen et al. [21] studied ammonia transport and glutamine synthesis in the hyperammonemic rat brain at a plasma ammonia concentration of 0.39 mM, using 15 N MRS at 7 T and surface-coil localization. A novel feature of their study is that the rate of ammonia transport into the brain, V trans, was calculated from the measured 15 N enrichment of plasma ammonia and the initial rate of 15 N incorporation into the brain [5- 15 N]GLN þ [2-15 N]GLN/GLU to be 0.13 ± 0.02 mmol/min/g. They proposed that the nitrogen leaving the brain by glutamine efflux (V efflux ) should be balanced by the rate of ammonia transport, V trans, and because two nitrogen atoms leave the brain with each glutamine molecule, the relationship V efflux ¼ 0. experiment. The higher magnetic field strength, combined with shimming using the echo planar version of the "fast automatic shimming technique by mapping along projections" (FASTMAP) [48] , resulted in an improved signal-to-noise ratio of the in vivo [5- 15 N]GLN peak, as seen from a comparison of the peak acquired in 30 min in Fig. 1b of Kanamori et al. [20] at 4.7 T with that acquired in 25 min in Fig. 4C of Cudalbu et al. [22] . Their localization method, single-shot inversion recovery based non-echo sequence (Section 2.6), is also an improvement over ISIS localization with a volume coil (Fig. 2 bottom) . It is encouraging that for the observation of brain [5- 15 N]glutamine in vivo, there were only very small differences in the peak areas between non-localized and localized spectra, suggesting that almost the entire [5- 15 N]GLN signal comes from the brain and not from surrounding tissues, as noted by Cudalbu et al. [22] . This is a point that was investigated earlier by in vitro measurements of [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] N]GLN in the brain and adjacent muscle tissues by Kanamori et al. [49] before initiating the in vivo 15 N studies of the rat brain.
For the calculation of the in vivo GS rate, the metabolic model of Cudalbu et al. [22] is simpler in that only the flux of nitrogen is considered. Glutamine efflux from the brain to the blood was considered to be negligibly small based on previous studies [20, 41] , and so was the flow of 15 N to aspartate based on their experimental observation. For the measurement of the rate of glutamine synthesis, the time-course of the total GLN measured by 1 d½5
where V nt is defined by these authors as the apparent rate of neurotransmission, and corresponds to the rate of cycling of GLU and GLN between neurons and astrocytes (V cycle of Shen et al. [21] ), and V in is the ammonia single-pass influx rate for which they used the value of 0.23 mmol/g/min reported previously [17, 21, 50] . The linear fit of the time evolution of the total Gln (Fig. 5A of Cudalbu et al. [22] ) provided a measure of the net glutamine accumulation (V syn -V nt ), to be 0.033 ± 0.001 mmol/g/min and the initial Gln concentration (Gln(0)) to be 2.3 mmol/g. [40,51e53] .
In summary, in comparing the rates of in vivo GS activities in hyperammonemia reported from the three laboratories to date, it is important to discern the underlying assumptions in each method and, where possible, complement in vivo MRS data with conventional biochemical assays, as this is feasible in animal brain.
In vivo glutamate dehydrogenase activity
Glutamate dehydrogenase (GDH) catalyzes the reversible reaction:
The in vivo activity of glutamate dehydrogenase (GDH) in the direction of reductive amination was measured in the rat brain at steady-state concentrations of brain ammonia and glutamate after the intravenous infusion of the substrate 15 (18), (19) and (23) in Cudalbu et al. [22] ) to obtain GDH rate of 0.029 ± 0.002 mmol/g per min at an 15 NH 4 Cl infusion rate of 4.5 mmol/g/h. The results from the two laboratories are in good agreement when the difference in the ammonia infusion rates is considered. The low in vivo activity compared to the reported in vitro activity of GDH measured at enzyme-saturating concentrations of the substrates, 900 mmol/g/h [55] , can most reasonably be attributed to the low in situ concentrations of ammonia and of 2-oxoglutarate (0.23 ± 0.05 mM) [40, 52, 54] relative to the K m values of the enzyme, 10e18 mM for NH 4 þ and 0.2e1.5 mM for 2-oxoglutarate [56, 57] . The two MRS studies strongly suggest that there is net GDH-catalyzed glutamate synthesis from ammonia in hyperammonemic brain, although the rate is slow. In the study by Cudalbu et al. [22] , the reverse component of GDH, oxidative deamination of GLU, converged to zero, suggesting that it is negligible. How to reconcile these findings with the prevalent view that the direction of the GDH reaction in the brain in vivo is mainly towards glutamate catabolism [58] is an area for future investigation.
Regulation of the GLN transport from glia to the ECF
In the glutamine/glutamate cycle, the pathway that had been the least well-understood was the mechanism of GLN transport from the glia, through the extracellular fluid (ECF), to the neuron (Fig. 1) . The identification and characterization of GLN transporters, SNAT3 [7] and SNAT1 [9] and SNAT2 [10] have significantly advanced our understanding of the transport mechanism. The current view of GLN transport in the adult brain is of GLN release from glia mainly mediated by the system N transporter, SNAT3, and of GLN uptake into neurons mainly mediated by system A transporters, SNAT1 and SNAT2 (reviewed by Br€ oer et al. [59] ).
SNAT3 mediates the co-transport of GLN with Na þ in exchange for H þ [7, 8] . In vitro, the transport is bi-directional and the direction of transport (influx or efflux) depends on the magnitudes of the driving forces [7] . A large transmembrane GLN gradient is expected to induce efflux despite the large inwardly directed driving force for Na þ and the outwardly directed force for H þ that would both tend to prevent efflux. These investigators proposed, based on in vitro studies, that extracellular GLN less than 0.4 mM induces GLN efflux. The GLN concentration in the ECF of the normal rat brain, measured by the zero-flow method [60] , is 0.385 ± 0.016 mM [61] . Alexander et al. [62] provided an estimate of 0.262 ± 0.012 mM for GLN ECF concentration in the rat cortex. Whole-brain [GLN], representing predominantly intracellular GLN, is~8 mM [51] . At least 80% of intracellular GLN is estimated to be in glia based on immunocytochemical studies [63, 64] also see Ref. [27] . Therefore, a reasonable estimate for the GLN gradient across the glial plasma membrane is 17 (¼6.4 mM/0.385 mM).
In view of the importance of glia-to-neuron GLN transport in the glutamine/glutamate cycle, we examined the transport characteristics of SNAT3 in vivo, which had not been attempted previously. We investigated the effect of the transmembrane GLN gradient on the rate of glial GLN release through the measurement of (a) GLN ECF collected by microdialysis, (b) the transmembrane GLN gradient and (c) the time-course of intracellular glial [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] N]GLN by 15 15 N-enrich brain GLN [26] .
As shown in Fig. 10 , GLN ECF increased gradually for 4 h, then showed a sharp increase at t ¼ 4.5 h of NH 4 Ac infusion. An interesting possibility is that this elevation was caused by the accumulation of GLN ECF when its neuronal uptake mediated by SNAT1 (with a K m of 0.3e0.49 mM in vitro [9, 65] ) became saturated. The [GLN] i /[GLN] ECF ratio was 9.6 ± 0.9 [26] , which is significantly lower than the ratio of~17 in the normal brain. GLN ECF then decreased substantially at t ¼ 4.9 ± 0.1 h. To investigate whether this decrease reflects the reduction of glial GLN efflux due to a decrease in the transmembrane GLN gradient, we compared the time-courses of intracellular and extracellular [5- 15 N]GLN during this period. As shown in Fig. 11a , intracellular, predominantly glial, [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] N]GLN increased progressively. By contrast, extracellular [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] N]GLN reached a plateau after T ¼ 1.9 h of 15 NH 4 Ac infusion (Fig. 11b upper  x-axis) , which corresponds to t ¼ 4.9 h of [ 14 Nþ 15 N]ammonia infusion (lower x-axis). These results strongly suggest that the efflux of glial [5- 15 N]GLN to ECF was reduced at this time, corresponding to a total NH 4 Ac infusion time of 4.9 ± 0.1 h when GLN ECF decreased substantially (Fig. 10) . Taken together, these results strongly suggest that when the transmembrane GLN gradient decreased to 9.6 ± 0.9, the driving force for GLN efflux was weakened, resulting in suppression of glial GLN release to ECF in vivo.
Other possible causes for the observed decrease in GLN ECF , such as osmotic disturbance and a change in the Na þ gradient, have been examined and ruled out. The partial suppression of glial GLN efflux to ECF when GLN ECF is elevated prevents excessive release, when its neuronal uptake by SNAT1 and SNAT2 has reached saturation and the rate of the gliato-neuron transport of GLN cannot be further increased. This suggests that the bi-directional nature of SNAT3 permits fine control of the rate of glial GLN efflux to ECF.
In conclusion, this study showed for the first time that (a) the combination of 15 GLN permits the study of how the GLN transporter SNAT3 operates in vivo and (b) the trans-membrane GLN gradient plays a key role in controlling glial GLN efflux to ECF at physiological Na þ gradient.
In vivo glutaminase activity
GLN released to ECF by SNAT3 is taken up into neurons mainly by SNAT1 and SNAT2 and hydrolyzed by glutaminase (GLNase) to GLU. The in vivo rate of the GLNase pathway, as measured by 15 N MRS at blood ammonia concentration of 0.4 mmol/g, was 1.1 ± 0.2 mmol/g/h [66] .
Rate of glutamate synthesis from leucine
Another pathway that can contribute to GLU synthesis by replenishment of its nitrogen is the transamination from leucine (LEU) to a-ketoglutarate to form GLU. The amine groups of aspartate and alanine, although these metabolites are present at higher concentrations in the brain than leucine, are in rapid exchange with the amine group of glutamate [51] [58] and do not contribute to de novo GLU synthesis because plasma aspartate and alanine have very low rates of uptake into the brain. By contrast, the essential amino acid LEU from dietary sources, when circulating in the blood, has a very high brain uptake index. In the brain, branched-chain aminotransferase (BCAT) catalyzes the transfer of the amine group from LEU to a-ketoglutarate to form GLU (Fig. 1) . Studies in cultured astrocytes, neurons and synaptosomes showed LEU to be a good source of GLU nitrogen ( [67] and references cited therein), but its role in the intact brain was unknown. To evaluate possible contribution of LEU as a source of GLU nitrogen, we measured the rate of GLU synthesis from LEU in the rat brain in vivo by 15 N NMR [13] .
Awake rats were fed exclusively by the intravenous infusion of glucose, amino acids (including LEU) and minerals and vitamins for two days. By the third day, all of the plasma and brain amino acids were at a steady-state and the brain GLU concentration was normal. 
, the observed values of V 2 and S 2 and the known K m (1.2 mM) of BCAT for LEU [68] , to be 0.35e0.9 mmol/g/h, with LEU providing~25% of glutamate nitrogen. Subsequently, Sakai et al. [15] fed [U- [15] ). Kinetic analyses showed that, at the physiological brain leucine concentration, leucine nitrogen provides~50% of brain glutamate nitrogen. Taken together, the results from the two laboratories clearly show that plasma leucine entering the brain is an important source of glutamate nitrogen. As described by Hall et al. [68] , the branched-chain aminotransferase has two isoforms, the mitochondrial BCAT m and the cytosolic BCAT c which represents 70% of the total BCAT activity in the brain. At the time of the enrichment studies described above, the distribution of BCAT in brain cell types (neuron vs glia) was unknown. Subsequent immunohistochemical studies showed a widespread expression of BCAT c in the cell bodies and axon terminals of glutamatergic and other types of neurons in the rat [14] and, more recently, in the human brain [69, 70] , while BCAT m is localized to astrocytes [71] . Taken together, the results strongly suggest that BCAT c -catalyzed transamination from LEU makes a significant contribution to the replenishment of neuronal GLU, which consists of metabolic and neurotransmitter pools.
As mentioned by Cole et al. [71] , there was a significant reduction in the concentrations of the branched-chain amino acids (BCAAs) in the hippocampus (as well as a decrease in BCAT c ) after brain injury in mice, that was associated with cognitive impairment. Interestingly, supplementing BCAAs in the drinking water completely restored the hippocampal BCAA concentrations and cognitive performance [72] . Importantly, similar results were shown in clinical trials with humans; administration of IV boluses of BCAAs to severely brain-injured patients resulted in some amelioration of their cognitive states [73, 74] . These results, combined with the demonstrated role of leucine as a provider of GLU nitrogen in vivo, suggest an intriguing possibility that the deprivation of hippocampal BCAAs is associated with a reduction in the excitatory neurotransmitter GLU that leads to cognitive impairment, and that supplementing dietary amino acid leucine may help towards recovery of cognitive function.
Glial uptake of the neurotransmitter GLU
Metabolic GLU is taken up by a uni-directional transporter into presynaptic vesicles to form the neurotransmitter pool of GLU (Fig. 1) . It is released by exocytosis into synaptic fluid, binds to the receptor and is rapidly taken up mainly into glia and is metabolized to GLN. We have taken the novel approach of taking into account the vesicular neurotransmitter pool of GLU in addition to its metabolic pools. We have used a combination of (a) in vivo 13 C/ 15 N MRS to examine the enrichment time-courses of intracellular GLU/ GLN and (b) microdialysis and gas-chromatography mass-spectrometry to monitor the enrichment time course of extracellular GLU [75] . Glial uptake of the neurotransmitter [5- In an earlier 15 N NMR study, we determined the rate of synthesis of glutamine to be 6.8 ± 0.7 mmol/g/h under identical experimental conditions [41] . This glutamine is synthesized from the metabolic glial GLU pool þ neurotransmitter GLU taken up into glia (Fig. 1) .
Comparison of the two rates strongly suggested that the neurotransmitter GLU provides 80e90% of the substrate GLU pool for GLN synthesis.
Summary and future perspectives
4.1. In vivo fluxes of the major pathways of GLU synthesis
Fig. 14 summarizes the in vivo rates of the major pathways that contribute to the synthesis and utilization of GLU, as measured in spontaneously-breathing rats by non-invasive 15 Thus, a potentially productive area for future research is to explore the complex pathways, involving less abundant neurochemicals, that control glutamate metabolism and its role in neurotransmission in the heterogeneous brain.
Potential for clinical study
How feasible is it to extend conventional 15 N MRS to the study of human brain? The following considerations are encouraging. A dramatic gain in sensitivity is expected when the volume of interest (VOI) is increased from <2.3 ml for the rat brain to, for example, 72 ml [77] , 144 ml [78, 79] or 210 ml [80] of the human brain used for in vivo 13 C MRS at 2.1 or 4 T. At present, administration of an 15 N-labelled precursor is likely to be essential for an in vivo 15 N MRS study of the human brain. [ 15 N]leucine, an essential amino acid that can safely be given intravenously, or as food supplement, is a promising candidate. As described in Section 3.5, the important roles of leucine in replenishing glutamate nitrogen [13, 15] , and in the restoration of cognitive function after brain injury in mice [72] have been demonstrated. In view of the recent advances in the characterization of BCAT in the human brain [69] and the encouraging outcome after the administration of branched-chain amino acids to brain-injured patients [74] , non-invasive studies of brain GLU after administration of the labelled leucine to explore its therapeutic potential may be a promising area for future investigation. Despite the improvements in sensitivity at high magnetic field, the main limitation in human studies is the power deposition in tissue by radiofrequency pulses, especially when using 1 H-decoupling (see for example [81, 82] ). However, power deposition for the proton-decoupling of 15 N is expected to be lower than the level successfully used in clinical 13 C MRS because typical one-bond 1 H- 15 N coupling (e.g.~90 Hz in GLN amide) is smaller than the one-bond 1 H-13 C coupling (e.g.~130 Hz in GLU C4). Another encouraging characteristic of 15 N is that for amine nitrogens of glutamate, glutamine and GABA (though not for the amide nitrogen of GLN), proton decoupling is not essential because the amine protons exchange rapidly with water protons at physiological pH, and, consequently, these amine nitrogens observed in vivo are virtual singlets without proton decoupling. Studies in the 1970s by the pioneers of high-resolution 15 N NMR showed that for amine nitrogens of amino acids, 1 J N-H of~74 Hz collapses due to rapid exchange with water protons at physiological pH [83] , 2 J N-C-H is very small (0.1e1.5 Hz: Table 146 , p.413 in Ref. [84] ) and 3 J N-C-C-Hb is 2.9 Hz [83] . Signal enhancement by NOE [85] which is nearly 4-fold in the amine nitrogens [83] (Section 2.1) is still desirable for sensitivity enhancement, but the power required to generate NOE is significantly lower than that for proton-decoupling when the WALTZ (Waugh-Levitz)16 bi-level decoupling sequence is used. For example, the required power was 0.25 W for NOE and 6 W for proton-decoupling in our in vivo experiment [20] . Furthermore, the radiofrequency power required to achieve a large bandwidth can be reduced if we focus, for example, on detection of the amine nitrogens of the excitatory neurotransmitter GLU and of the inhibitory neurotransmitter GABA, because GABA nitrogen, although well resolved from the a nitrogens of GLU/GLN, at~6 ppm upfield [84] resonates in the same À340 to À348 ppm region, permitting selective excitation. Finally, ongoing improvement in the design of 1 H- 13 C coil (e.g. Ref. [81] ) that achieves a 1.4 fold enhancement in sensitivity without an increase in the power deposition for clinical proton-decoupled 13 C MRS at 7 T, may eventually be adapted for clinical 15 N studies. We hope that these considerations may be useful in designing well-focused clinical in vivo 15 N MRS studies in the future.
